Per the U.S. DoD, * Indicates a "small business" classification and ** indicates a "small disadvantaged business". NOTE: the U.S. DoD only publicly reports contracts valued at $6.5 million USD or greater.
The contract language is EXACTLY as it appears on the official U.S. DoD website (http://www.defense.gov/contracts/) unless otherwise noted.
Contractor: MediVector, Incorporated
Department: Defense Threat Reduction Agency
MediVector Inc.*, Boston, Massachusetts, has been awarded a maximum $9,135,695 modification (PZ0002) to previously awarded contract HDTRA1-12-C-0031 for the capability to manufacture Favipiravir (T-705) therapeutic in the U.S. The modification brings the total cumulative face value of the contract to $211,303,678 from $202,167,983. Work will be performed at the prime contractor location of Boston, Massachusetts, as well as at subcontractor locations of Tokyo, Japan; West Deptford, New Jersey; Somerset, New Jersey; Franklin, Massachusetts; Essex, Massachusetts; Audubon, Pennsylvania; Alachua, Florida; Carlsbad, California; Albany, New York; and, Dunwoody, Georgia, with an expected completion date of March 13, 2017. No additional funds are being obligated at the time of award. The Defense Threat Reduction Agency, Fort Belvoir, Virginia, is the contracting activity.
Total Contract Value: $9,135,695